Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QM103
- Development stage
- Unknown
- Lead developer
- 北京奇迈永华
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
QM103 is an investigational cell therapy being developed by Beijing Qimai Yonghua Biotechnology for the treatment of relapsed or refractory multiple myeloma. It specifically targets B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells. The therapy is administered as an intravenous injection on a multi-dose schedule (days 1, 8, and 15 of a 28-day cycle). It is currently undergoing Phase I/II clinical evaluation in China to determine its safety, tolerability, and preliminary anti-myeloma activity in patients who have failed standard therapies.
- Other names
- QM103 cell injectionQM-103 cell injectionQM 103 cell injection
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on QM103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QM103.